Payment Data Systems Inc (NASDAQ:PYDS) had an increase of 55.45% in short interest. PYDS’s SI was 310,900 shares in April as released by FINRA. Its up 55.45% from 200,000 shares previously. With 233,300 avg volume, 1 days are for Payment Data Systems Inc (NASDAQ:PYDS)’s short sellers to cover PYDS’s short positions. The SI to Payment Data Systems Inc’s float is 4.15%. The stock decreased 2.52% or $0.06 during the last trading session, reaching $2.32. About 24,526 shares traded. Payment Data Systems, Inc. (NASDAQ:PYDS) has risen 72.51% since April 15, 2018 and is uptrending. It has outperformed by 68.14% the S&P500. Some Historical PYDS News: 22/04/2018 – DJ Payment Data Systems Inc, Inst Holders, 1Q 2018 (PYDS); 29/03/2018 – Payment Data Systems Announces Record Revenues of $5.6 Million for Fourth Quarter and $14.6 Million for Fiscal 2017; 29/03/2018 – Payment Data Systems 4Q Loss/Shr 13c; 07/03/2018 Payment Data Systems at Non-Deal Roadshow Hosted By Maxim Today; 29/03/2018 – Payment Data Systems 4Q Rev $5.6M; 15/05/2018 – Payment Data Systems 1Q Loss/Shr 9c; 25/04/2018 – Payment Data Systems Coverage Assumed by Maxim Group at Buy; 15/05/2018 – PAYMENT DATA SYSTEMS INC – EXPECT RECORD ANNUAL REVENUES FOR 2018; 15/05/2018 – Payment Data Systems 1Q Rev $5.84M; 30/05/2018 – Payment Data Systems Launches Corporate Responsibility Program
BidaskScore has decreased XBiotech (NASDAQ:XBIT) stock rating to “Hold” in a report revealed to clients and investors on 14 April.
More important recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Seekingalpha.com which released: “Our Take On XBiotech – Seeking Alpha” on April 01, 2019, also Globenewswire.com published article titled: “Research Report Identifies Net 1 UEPS Technologies, XBiotech, Rambus, Vector Group, Collectors Universe, and Gulf Island Fabrication with Renewed Outlook â€” Fundamental Analysis, Calculating Forward Movement – GlobeNewswire”, Benzinga.com published: “Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering – Benzinga” on March 21, 2019. More interesting news about XBiotech Inc. (NASDAQ:XBIT) was released by: Benzinga.com and their article: “Daily Biotech Pulse: Immutep Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback – Benzinga” with publication date: March 22, 2019.
The stock decreased 3.49% or $0.33 during the last trading session, reaching $9.13. About 217,345 shares traded or 21.90% up from the average. XBiotech Inc. (NASDAQ:XBIT) has risen 90.53% since April 15, 2018 and is uptrending. It has outperformed by 86.16% the S&P500. Some Historical XBIT News: 02/04/2018 XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer; 02/04/2018 – XBIOTECH – WILL USE ITS TECHNOLOGY TO ADVANCE DEVELOPMENT OF TRUE HUMAN(TM )ANTI-NY-ESO-1 MONOCLONAL ANTIBODY, 12D7; 16/04/2018 – XBIOTECH INC – UPCOMING PHASE 2 CLINICAL STUDIES IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) AND HIDRADENITIS SUPPURATIVA (HS); 20/04/2018 – DJ XBiotech Inc, Inst Holders, 1Q 2018 (XBIT); 22/05/2018 – XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis; 16/04/2018 – XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 02/04/2018 – XBIOTECH INC – HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG; 02/04/2018 – XBIOTECH INC – OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG, A SWISS BIOTECHNOLOGY COMPANY; 16/04/2018 – XBIOTECH INC – CONDUCTING FINAL PREPARATIONS FOR STUDY LAUNCH INCLUDING FIRST CLINICAL SITE INITIATION SCHEDULED LATER THIS MONTH; 02/04/2018 – XBIOTECH IN-LICENSES ANTI-NY-ESO-1 ANTIBODY FROM CT ATLANTIC
XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $329.12 million. The company’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.
More notable recent Payment Data Systems, Inc. (NASDAQ:PYDS) news were published by: Globenewswire.com which released: “Payment Data Systems to Participate at the BTIG Financials Conference – GlobeNewswire” on March 19, 2019, also Globenewswire.com with their article: “Payment Data Systems Announces Record 2018 Financial Results – GlobeNewswire” published on March 27, 2019, Globenewswire.com published: “Payment Data Systems’ Best-in-Class Akimbo Commercial Mastercard Product Continues Strong Growth in Targeted Healthcare Vertical – GlobeNewswire” on April 01, 2019. More interesting news about Payment Data Systems, Inc. (NASDAQ:PYDS) were released by: Nasdaq.com and their article: “Payment Data Systems to Announce Fourth Quarter and Full Year 2018 Financial Results and Provide Company Update on Wednesday, March 27, 2019 – Nasdaq” published on March 25, 2019 as well as Nasdaq.com‘s news article titled: “Payment Data Systems to Present at the Spring Investor Summit on April 1, 2019 – Nasdaq” with publication date: March 28, 2019.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.